A Systematic Literature Review of Health-related Quality of Life Measures for Women with Hypoactive Sexual Desire Disorder and Female Sexual Interest/Arousal Disorder
- PMID: 34481749
- DOI: 10.1016/j.sxmr.2021.07.003
A Systematic Literature Review of Health-related Quality of Life Measures for Women with Hypoactive Sexual Desire Disorder and Female Sexual Interest/Arousal Disorder
Abstract
Introduction: Hypoactive Sexual Desire Disorder (HSDD) / Female Sexual Interest/Arousal Disorder (FSIAD) impacts health-related quality of life (HRQoL) of women and their partners, yet existing measures fail to adequately capture relevant concepts (ie, what is essential to measure including symptoms/impacts) important to women with HSDD/FSIAD.
Objectives: To identify HRQoL tools used to assess women with HSDD/FSIAD, and to evaluate their psychometric properties (ie, reliability, validity, and responsiveness).
Methods: We conducted searches in PubMed, Embase and PsychINFO from June 5, 1989 to September 30, 2020 for studies in women with HSDD/FSIAD and psychometric analyses (English only). Principles of the Preferred Reporting Items for Systematic reviews and Meta-Analyses, the COnsensus-based Standards for the selection of health Measurement INstruments Risk of Bias Checklist and other psychometric criteria were applied. Based on this search, 56 papers were evaluated including 15 randomized-controlled trials, 11 observational/single arm/open label studies, and 30 psychometric studies.
Results: Of the 18 measures identified, the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Revised (FSDS-R) were included in most studies (> 50%). General HRQoL instruments were not used in any of the clinical trials; the SF-12, SF-36 and EQ-5D-5L were reported in two observational studies. No instruments achieved positive quality ratings across all psychometric criteria. The FSFI, FSDS-R, Sexual Event Diary (SED) and the Sexual Desire Relationship Distress Scale (SDRDS), were the only measures to receive a positive rating for content validity.
Conclusion: Reliable and valid HRQoL measures that include sexual desire and distress are needed to provide a more systematic and comprehensive assessment of HRQoL and treatment benefits in women with HSDD/FSIAD. While inferences about HRQoL are limited due to the lack of uniformity in concepts assessed and limited psychometric evaluation of these measures in women with HSDD/FSIAD, opportunities exist for the development of reliable and validated tools that comprehensively measure the most relevant and important concepts in women with HSDD/FSIAD. Lim-Watson MZ, Hays RD, Kingsberg S, et al. A systematic literature review of health-related quality of life measures for women with Hypoactive Sexual Desire Disorder and Female Sexual Interest/Arousal Disorder. Sex Med Rev 2022;10:23-41.
Keywords: Female Sexual Interest/Arousal Disorder; Health-Related Quality of Life; Hypoactive Sexual Desire Disorder; Patient-Reported Outcome; Psychometric.
Copyright © 2021 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis.J Sex Med. 2015 Nov;12(11):2095-104. doi: 10.1111/jsm.13037. J Sex Med. 2015. PMID: 26745616
-
Sexual counseling for female sexual interest/arousal disorders: a randomized controlled trial based on the "good enough sex" model.J Sex Med. 2024 Jan 30;21(2):153-162. doi: 10.1093/jsxmed/qdad168. J Sex Med. 2024. PMID: 38181124 Clinical Trial.
-
A systematic review of tools designed for teacher proxy-report of children's physical literacy or constituting elements.Int J Behav Nutr Phys Act. 2021 Oct 8;18(1):131. doi: 10.1186/s12966-021-01162-3. Int J Behav Nutr Phys Act. 2021. PMID: 34620185 Free PMC article.
-
Interventions for interpersonal communication about end of life care between health practitioners and affected people.Cochrane Database Syst Rev. 2022 Jul 8;7(7):CD013116. doi: 10.1002/14651858.CD013116.pub2. Cochrane Database Syst Rev. 2022. PMID: 35802350 Free PMC article.
-
Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD013167. doi: 10.1002/14651858.CD013167.pub2. Cochrane Database Syst Rev. 2022. PMID: 35005781 Free PMC article.
Cited by
-
Methodological quality of 100 recent systematic reviews of health-related outcome measurement instruments: an overview of reviews.Qual Life Res. 2024 Oct;33(10):2593-2609. doi: 10.1007/s11136-024-03706-z. Epub 2024 Jul 3. Qual Life Res. 2024. PMID: 38961010 Free PMC article. Review.
-
Appropriateness of the EQ-5D-5L in capturing health-related quality of life in individuals with transfusion-dependent β-thalassemia: a mixed methods study.Health Qual Life Outcomes. 2024 Jul 11;22(1):54. doi: 10.1186/s12955-024-02265-8. Health Qual Life Outcomes. 2024. PMID: 38992661 Free PMC article.
-
Pooled Analysis Confirms Flibanserin's Unimpressive Efficacy, Raises Measurement Questions: A Commentary on Simon et al.Sex Med. 2022 Dec;10(6):100579. doi: 10.1016/j.esxm.2022.100579. Epub 2022 Nov 1. Sex Med. 2022. PMID: 36328924 Free PMC article. No abstract available.
-
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder.Sex Med. 2022 Dec;10(6):100570. doi: 10.1016/j.esxm.2022.100570. Epub 2022 Nov 10. Sex Med. 2022. PMID: 36400683 Free PMC article.